Citius Pharmaceuticals, Inc. (CTXR) Form 8-K — May 15, 2026
Citius Pharmaceuticals (CTXR) reported fiscal Q2 2026 results showing $1.7 million in net product revenue from its LYMPHIR launch, contributing to $5.6 million in first-half revenue compared to zero in the prior year. The company reported a net loss of $21.2 million for the quarter, heavily influenced by a $19.7 million one-time charge for a CMO contract cancellation. Subsequent to the quarter, Citius secured $41.5 million in combined financing, including a $5 million registered direct offering by the parent and up to $36.5 million in debt and equity financing for its majority-owned subsidiary, Citius Oncology (CTOR).
Key figures
- Revenue
- 5611409
- Total Debt
- 63456026
- Revenue Yoy
- 100%
- Total Assets
- 132540579
- Cash Position
- 4590174
- Ga Expense
- 26391101
- Rd Expense
- 1633518
- Cash Runway
- November 2026
- Gross Margin
- 80%
- Gross Profit
- 1338420
- Debt Facility Size
- 25000000
- Gain On Sale Of NOLs
- 3833277
- Shares Outstanding
- 22376427
- Cmo Cancellation Charge
- 19700000
- Direct Offering Proceeds
- 5000000
- Stock Based Compensation
- 3788275
- Warrant Exercise Proceeds
- 11500000
Price after filing
Close on the filing date to close N calendar days later (from $0.72). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.